CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Sodium phenylbutyrate

Sodium phenylbutyrate

Last Updated: July 6, 2015

Result type: Reports

Project Number: SR0452-000

Product Line: Reimbursement Review

Generic Name: Sodium phenylbutyrate

Brand Name: Pheburane

Manufacturer: Médunik Canada

Therapeutic Area: Urea cycle disorders

Indications: Urea cycle disorders

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 15, 2016

Recommendation Type: List

Sodium phenylbutyrate

Files